Detail Information of Xenobiotics

General Information of Xenobiotics (ID: XEO00195)
Xenobiotics Name
Crizotinib
Xenobiotics Type
Pharmaceutical Agent(s)
Classification
Approved/Marketed Drug
Structure
<iframe style="width: 300px; height: 300px;" frameborder="0" src="https://embed.molview.org/v1/?mode=balls&cid=11626560"></iframe>
3D MOL 2D MOL
PubChem CID
11626560
DME(s) Modulated by This Xenobiotics
DME(s) Inhibited by This Xenobiotics
Cytidine aminohydrolase (CDA) DME Info Homo sapiens [1]
DME(s) Induced by This Xenobiotics
Cytochrome P450 3A4 (CYP3A4) DME Info Homo sapiens [2]
Fatty acid desaturase 2 (FADS2) DME Info Homo sapiens [3]
HMG-CoA reductase (HMGCR) DME Info Homo sapiens [3]
References
1 Enhancement of the antiproliferative activity of gemcitabine by modulation of c-Met pathway in pancreatic cancer. Curr Pharm Des. 2013;19(5):940-50.
2 Prediction of crizotinib-midazolam interaction using the Simcyp population-based simulator: comparison of CYP3A time-dependent inhibition between human liver microsomes versus hepatocytes. Drug Metab Dispos. 2013 Feb;41(2):343-52.
3 Multi-parameter in vitro toxicity testing of crizotinib, sunitinib, erlotinib, and nilotinib in human cardiomyocytes. Toxicol Appl Pharmacol. 2013 Oct 1;272(1):245-55.

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.